FYARRO net product sales reached $3.4 million for the second quarter of 2022.

A product-specific permanent J-code (J9331) for FYARRO from Centers for Medicare and Medicaid Services (CMS) became effective on July 1, 2022.

The PRECISION 1 trial continues to ramp up, with activation of additional clinical trial sites and patient enrollment.

Cash and cash equivalents on June 30, 2022 were $118.7 million.